Reference : Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the respon...
Scientific journals : Article
Life sciences : Biotechnology
Life sciences : Genetics & genetic processes
Life sciences : Microbiology
http://hdl.handle.net/2268/26649
Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study
English
Dideberg, Vinciane mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
Farnir, Frédéric mailto [Université de Liège - ULg > Département de productions animales > Biostatistique, économie, sélection animale >]
Bertoli, Sabrina mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Vermeire, S. [> > > >]
Rutgeerts, P. [> > > >]
De Vos, M. [> > > >]
Van Gossum, A. [> > > >]
Belaiche, Jacques mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie]
Bours, Vincent mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine]
May-2006
Pharmacogenetics and Genomics
Lippincott Williams & Wilkins
16
5
369-373
Yes (verified by ORBi)
International
1744-6872
Philadelphia
[en] Crohn's disease ; infliximab ; lymphotoxin alpha ; pharmacogenetics
[en] A haplotype in the lymphotoxin alpha (LTA) gene has been associated with a lack of response to infliximab in a small cohort of Crohn's disease (CD) patients. The present study aimed to confirm the implication of this haplotype in the response to infliximab in a larger cohort of Caucasian patients. The response to the first infusion with infliximab was evaluated in 214 Caucasian patients with either luminal (n = 150) or fistulising (n = 64) CD. Clinical response was based on the decrease in CID Activity Index (luminal) or on the evolution in the fistula discharge (fistulising). Biological response was assessed in 139 patients who had elevated C-reactive protein (CRP) before treatment and for whom CRP values were also available after treatment. A positive biological response was defined as a decrease in CRP of at least 25%. The patients were genotyped for six polymorphisms in the LTA gene. A positive clinical response was present in 65.4% of the patients and a positive biological response was observed in 80.6% of the patients. No association was found with any of the studied polymorphisms, nor with the previously published LTA haplotype and the response to infliximab. We could not confirm an association between the LTA locus and clinical or biological response to infliximab in a large cohort of CID patients. Pharmacogenetics and Genomics 16:369-373 (c) 2006 Lippincott Williams
http://hdl.handle.net/2268/26649
10.1097/01.fpc.0000204993.91806.b1

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Pharmacogenet Genomics 2006 16 369-373.pdfPublisher postprint77.74 kBRequest copy
Open access
Lymphotoxin alpha gene in Crohn's disease patients...2006.pdfAuthor postprint159.2 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.